XML 76 R65.htm IDEA: XBRL DOCUMENT v3.20.4
Note 13 - Segment Information - Operating Segment Information (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2020
Dec. 31, 2019
Total revenues [1] $ 34,172 $ 31,655 $ 95,973 $ 83,479
Gross profit (loss) 20,653 14,803 62,278 46,593
Reconciling items [2] (26,380) (19,880) (64,867) (42,471)
(Loss) before income taxes (5,727) (5,077) (2,589) 4,122
Corporate, Non-Segment [Member]        
Total revenues [1] 0 229 0 2,442
Gross profit (loss) (140) (18) (76) 395
Sterilization and Disinfection Control [Member] | Operating Segments [Member]        
Total revenues [1] 13,077 11,619 37,696 35,823
Gross profit (loss) 9,308 8,101 28,098 25,334
Instruments [Member] | Operating Segments [Member]        
Total revenues [1] 8,971 10,014 24,209 28,518
Gross profit (loss) 5,368 6,526 14,909 18,164
Biopharmaceutical Development [Member] | Operating Segments [Member]        
Total revenues [1] 8,711 5,637 23,791 5,637
Gross profit (loss) 4,616 (1,294) 15,294 (1,294)
Cold Chain Monitoring [Member] | Operating Segments [Member]        
Total revenues [1] 3,413 4,156 10,277 11,059
Gross profit (loss) $ 1,501 $ 1,488 $ 4,053 $ 3,994
[1] Intersegment revenues are not significant and are eliminated to arrive at consolidated totals.
[2] Reconciling items include selling, general and administrative, research and development, interest expense and amortization of debt discount, and other (income) expenses.